BaroFold and Avecia Announce Development and Manufacturing Agreement.BOULDER, Colo. & TEES VALLEY The Tees Valley is an area the North East of England. It can be described as "greater Teesside" and consists of the four unitary authorities created by the breakup of the County of Cleveland in 1996: Hartlepool, Middlesbrough, Redcar & Cleveland, and Stockton-On-Tees along with , England -- BaroFold, Inc., developers of PreEMT[TM] protein processing technology, and Avecia Biologics Limited have entered into an agreement for process development and cGMP manufacture of BaroFold's lead, proprietary compound, BaroFeron[TM], interferon beta-1b interferon beta-1b Betaferon (UK), Betaseron Pharmacologic class: Biological response modifier Therapeutic class: Antiviral, immunoregulator Pregnancy risk category C Action. Interferon betas interferon beta Fibroblast interferon IFN-β A 20 kD anti-viral protein with 30% 'homology' with IFN alpha, encoded on chromosome 9, produced by fibroblasts in response to viruses or polyribonucleotides are used as therapeutic agents in the treatment of multiple sclerosis and other autoimmune disorders Autoimmune Disorders DefinitionAutoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction. . The program involves Avecia integrating operation of PreEMT[TM] technology alongside other stages of protein purification Protein purification is a series of processes intended to isolate a single type of protein from a complex mixture. Protein purification is vital for the characterisation of the function, structure and interactions of the protein of interest. in both pilot and cGMP facilities. Avecia has both installed a PreEMT[TM] Plus system in its development laboratory and completed manufacture of BaroFeron[TM]. Dr. Jeff Cleland, Vice President of Therapeutic Development at BaroFold said "We are pleased to be working with Avecia on our lead compound and are confident that their competencies in process science and engineering will deliver an solid process for BaroFeron[TM], provide cGMP product for our clinical trials and facilitate the further development of PreEMT[TM] technology for BaroFold and our partners." Completing the scale-up of the drug manufacturing process will be a significant milestone, providing a platform to potentially expand the use of PreEMT[TM] technology to address areas of fundamental importance for protein manufacturing. BaroFold's technology potentially enables its' corporate partners to develop next generation protein biologics to meet the need for safer and cost effective new therapeutics. Dr. Stephen Taylor, Avecia's Business Director, said: "We are delighted to be working with BaroFold on development of a manufacturing process for BaroFeron. We are also excited that they have recognized Avecia's track record of technological innovation and have chosen to work with us on scale-up of the novel PreEMT[TM] technology." Under this program, Avecia will carry out development work to optimize and scale-up the drug manufacturing process for BaroFeron[TM], using BaroFold's proprietary PreEMT[TM] protein processing technology. About BaroFold BaroFold is a bio-therapeutics company focused on developing and commercializing improved protein therapeutics based, in part, on its proprietary PreEMT[TM] technology. The PreEMT[TM] technology is intended to enable improved, safer, proprietary protein therapeutics, potentially providing enhanced product life-cycle and creating new protein therapeutics through the use of a patented protein refolding technology. PreEMT[TM] involves the use of high hydrostatic pressure hydrostatic pressure The pressure exerted by a fluid at equilibrium at a given point within the fluid, due to the force of gravity. Hydrostatic pressure increases in proportion to depth measured from the surface because of the increasing weight of fluid to potentially disaggregate See disaggregated. and refold Re`fold´ v. t. 1. To fold again. proteins. BaroFold is currently developing its own proprietary protein therapeutic portfolio including BaroFeron[TM], a proprietary product candidate. BaroFold also develops select protein therapeutics in partnerships with other biotechnology and pharmaceutical companies. For additional information about the company, please visit www.barofold.com. About Avecia Avecia is a privately owned biotechnology group of companies with recognised leading positions in the process development and manufacture of biopharmaceutical and oligonucleotide Oligonucleotide A deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequence composed of two or more covalently linked nucleotides. Oligonucleotides are classified as deoxyribooligonucleotides or ribooligonucleotides. medicines. It is also a leading developer of bio-defence vaccines. The Group's Tees Valley, UK site has been developing processes and making protein-based biologics to cGMP since 1998. Products currently being worked on include medicines targeted at forms of cancer, heart conditions, stroke, growth and blood disorders blood disorders, n.pl hematologic dyscrasias that affect the component cells and plasma elements of the blood. They are generally divided into two broad groups: those in which an increase in bulk occurs (e.g. . Customers range from some of the world's largest pharmaceutical companies to small innovative biotech start-up businesses. This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc initiation and progress of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion